ValuEngine downgraded shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a research note issued to investors on Friday, February 2nd.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Celsion from a buy rating to a hold rating in a research report on Tuesday, October 17th. Oppenheimer started coverage on shares of Celsion in a research report on Tuesday, November 21st. They set an outperform rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $11.90.
Shares of Celsion (NASDAQ:CLSN) opened at $2.20 on Friday. The stock has a market cap of $35.34, a PE ratio of -0.38 and a beta of 1.81. Celsion has a 1 year low of $1.24 and a 1 year high of $6.06.
A hedge fund recently bought a new stake in Celsion stock. Virtu Financial LLC purchased a new stake in shares of Celsion Co. (NASDAQ:CLSN) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned about 0.24% of Celsion at the end of the most recent quarter. 2.05% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Celsion (CLSN) Stock Rating Lowered by ValuEngine” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/valuengine-lowers-celsion-clsn-to-strong-sell.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.